前列腺多参数MR成像中我们遗漏了什么?假阴性前列腺癌的特征分析
该回顾性单中心研究纳入100例连续行多参数MR成像后接受根治性前列腺切除术的患者,以全mount病理为参考,162个病灶中136个(84%)被正确识别,26个(16%)被遗漏;遗漏病灶中65%为Gleason 3+4,回顾性PI-RADS v2评分多为1-3分,58%的遗漏病灶二次阅片未见或判为良性。
要点
- 多参数MR可遗漏临床重要前列腺癌,遗漏病灶中65%为Gleason 3+4。
- 遗漏病灶回顾性PI-RADS v2评分以1-3分为主,58%二次阅片未见或判为良性。
- 8个病灶大小被低估,占全部病灶的5%。
核心结论
- 多参数MR成像可遗漏临床重要前列腺癌病灶或低估其大小,遗漏病灶中58%在二次阅片时未见或判为良性,需要新方法降低假阴性率。
研究设计与样本
- 经当地机构审查委员会批准的HIPAA合规回顾性单中心研究,纳入100例连续接受多参数MR成像并随后行根治性前列腺切除术的患者。
- 由对MR表现不知情的泌尿生殖病理医师在全mount病理切片上勾画前列腺癌,两名阅片者将病灶与前瞻性MR报告进行对应。
- 病理检查排除80个临床不重要病灶(<5 mm;Gleason评分3+3)。
- 同一两名阅片者(对组织病理结果不设盲)回顾性复阅MR遗漏的癌症,并赋予PI-RADS v2评分。
诊断标准与关键数值
- 以全mount病理为参考标准,162个病灶中136个(84%)被多参数MR正确识别,26个(16%)被遗漏。
- 遗漏病灶Gleason评分:3+4为17个(65%),4+3为1个(4%),4+4为7个(27%),4+5为1个(4%)。
- 遗漏病灶回顾性PI-RADS v2评分:1分8个,2分7个,3分6个,4分5个。
- 按患者计算,100例中99例(99%)多参数MR检出临床重要前列腺癌,26例(26%)至少遗漏一个临床重要肿瘤,8例(8%)病灶大小被低估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To characterize clinically important prostate cancers missed at multiparametric (MP) magnetic resonance (MR) imaging. Materials and Methods The local institutional review board approved this HIPAA-compliant retrospective single-center study, which included 100 consecutive patients who had undergone MP MR imaging and subsequent radical prostatectomy. A genitourinary pathologist blinded to MP MR findings outlined prostate cancers on whole-mount pathology slices. Two readers correlated mapped lesions with reports of prospectively read MP MR images. Readers were blinded to histopathology results during prospective reading. At histopathologic examination, 80 clinically unimportant lesions (<5 mm; Gleason score, 3+3) were excluded. The same two readers, who were not blinded to histopathologic findings, retrospectively reviewed cancers missed at MP MR imaging and assigned a Prostate Imaging Reporting and Data System (PI-RADS) version 2 score to better understand false-negative lesion characteristics. Descriptive statistics were used to define patient characteristics, including age, prostate-specific antigen (PSA) level, PSA density, race, digital rectal examination results, and biopsy results before MR imaging. Student t test was used to determine any demographic differences between patients with false-negative MP MR imaging findings and those with correct prospective identification of all lesions. Results Of the 162 lesions, 136 (84%) were correctly identified with MP MR imaging. Size of eight lesions was underestimated. Among the 26 (16%) lesions missed at MP MR imaging, Gleason score was 3+4 in 17 (65%), 4+3 in one (4%), 4+4 in seven (27%), and 4+5 in one (4%). Retrospective PI-RADS version 2 scores were assigned (PI-RADS 1, n = 8; PI-RADS 2, n = 7; PI-RADS 3, n = 6; and PI-RADS 4, n = 5). On a per-patient basis, MP MR imaging depicted clinically important prostate cancer in 99 of 100 patients. At least one clinically important tumor was missed in 26 (26%) patients, and lesion size was underestimated in eight (8%). Conclusion Clinically important lesions can be missed or their size can be underestimated at MP MR imaging. Of missed lesions, 58% were not seen or were characterized as benign findings at second-look analysis. Recognition of the limitations of MP MR imaging is important, and new approaches to reduce this false-negative rate are needed. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Borofsky S, George AK, Gaur S, et al. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology. 2017. PMID: 29053402. doi:10.1148/radiol.2017152877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。